(NASDAQ: ACIU) Ac Immune Sa's forecast annual revenue growth rate of 45.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.13%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Ac Immune Sa's revenue in 2025 is $34,510,975.On average, 3 Wall Street analysts forecast ACIU's revenue for 2025 to be $3,741,893,109, with the lowest ACIU revenue forecast at $456,867,215, and the highest ACIU revenue forecast at $10,041,037,700. On average, 2 Wall Street analysts forecast ACIU's revenue for 2026 to be $2,785,383,858, with the lowest ACIU revenue forecast at $1,667,816,362, and the highest ACIU revenue forecast at $3,902,951,354.
In 2027, ACIU is forecast to generate $12,567,864,837 in revenue, with the lowest revenue forecast at $11,406,618,827 and the highest revenue forecast at $13,729,110,847.